Navigation Links
Uroplasty on Preliminary List of Additions to Russell 3000® and Russell Global® Indexes
Date:6/13/2011

MINNEAPOLIS, June 13, 2011 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced it has been included on a list of preliminary additions to the Russell 3000® Index and the Russell Global® Index posted by Russell Investments on June 10, 2011 on www.russell.com. These changes are expected to go into effect after the close of trading on Friday, June 24, 2011.  

"The preliminary addition of Uroplasty to the Russell 3000 and Russell Global indexes is a testament to the progress we have made in building valuation," said David Kaysen, president and CEO of Uroplasty.  "It should help expand awareness of our company, especially among institutional investors, as we continue to execute our growth strategy for our Urgent PC® and Macroplastique® product lines."

The Russell 3000 Index measures the performance of the largest 3000 U.S. companies, representing approximately 98% of the investable U.S. equity market. The Russell Global Index measures the performance of the global equity market based on all investable equity securities, and includes approximately 10,000 securities in 48 countries and covers 98% of the investable global market. The Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for passive and active investment strategies.  The indexes are reconstituted annually.

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared system that delivers posterior tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique® Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

For Further Information:

Uroplasty, Inc.

David Kaysen, President and CEO, or

Medi Jiwani, Vice President, CFO, Treasurer

952.426.6140


EVC Group

Doug Sherk/Jenifer Kirtland (Investors), 415.896.6820

Chris Gale (Media), 646.201.5431




'/>"/>
SOURCE Uroplasty, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Uroplastys Dave Kaysen to Ring NASDAQ Closing Bell
2. Uroplasty Reports Financial Results for the Fiscal Fourth Quarter and Full Year 2011
3. Uroplasty to Present at the JMP Securities Research Conference
4. Clinical Studies Results of Uroplasty Products Scheduled for Presentation at Three Professional Meetings
5. Uroplasty Announces Expanded Insurance Coverage of Posterior Tibial Nerve Stimulation (PTNS) Delivered Using the Urgent® PC Neuromodulation System
6. Uroplasty to Present at ROTH Capital Partners 23rd Annual OC Growth Stock Conference
7. Uroplasty Reports Financial Results for the Third Quarter FY2011
8. Uroplasty to Issue Third Quarter 2011 Results on January 27, 2011
9. Uroplasty Announces Addition of Robert Kill to its Board of Directors
10. Additional Regional Medicare Carrier Initiates Coverage for Posterior Tibial Nerve Stimulation (PTNS) Delivered via Uroplastys Urgent® PC Neuromodulation System
11. Uroplasty Inc. Announces CPT® Category I Code and Associated Reimbursement Value for Posterior Tibial Nerve Stimulation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... India , February 17, 2017 According ... (Airborne Particle Counters, Liquid Particle Counters), Application (Cleanroom Monitoring, Contamination Monitoring ... Forecast to 2021" published by MarketsandMarkets, the market is expected to ... 2016, at a CAGR of 3.7% from 2016 to 2021. ... ...
(Date:2/17/2017)... Research and Markets has announced the addition of ... their offering. ... separate comprehensive analytics for the US, Canada , ... , Latin America , and Rest of World. ... Also, a six-year historic analysis is provided for these markets. Market data ...
(Date:2/17/2017)...  BioDigital, Inc., creators of the BioDigital Human ... body mapping technology with eClinicalWorks, a privately held ... be used to capture and present dermatology exam ... body. BioDigital pilots show using a body to ... the precision of clinical annotations compared to standard ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... February 17, 2017 , ... Smiles by Seese is ... in Davidson, NC. Dr. Brian Seese leads the practice as a skilled and highly ... one roof. Smiles by Seese serves patients of all ages with excellence in general, ...
(Date:2/17/2017)... ... February 17, 2017 , ... For ... assistance management solution to the exhibit floor for the 2017 HIMSS Conference ... , From Feb. 19–23, 2017, more than 40,000 healthcare industry professionals are expected ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... organizations, has been named a finalist in the 8th Annual DecisionHealth Platinum Awards ... healthcare delivery system. Qualis Health’s work is recognized across multiple award categories, highlighting ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... and focusing on all facets of clinical trial planning and management. Pharmica discussed ... engagement, and more. In addition, attendees stopping by Pharmica’s booth were able to ...
(Date:2/17/2017)... CREEK, CO (PRWEB) , ... February 17, 2017 , ... ... second annual International Healing NET Foundation Summit from February 21 - 23 in Beaver ... NET Foundation (HNF). This marks the Summit’s second year in Beaver Creek, hosting over ...
Breaking Medicine News(10 mins):